Clearmind Medicine (NASDAQ:CMND) Shares Down 11.2% – Time to Sell?

Clearmind Medicine Inc. (NASDAQ:CMND) shares were down 11.2% on Tuesday . The stock traded as low as $0.9199 and last traded at $1.03. 3,049,006 shares traded hands during mid-day trading, an increase of 233% from the average session volume of 915,250 shares. The stock had previously closed at $1.16.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Clearmind Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th.

Clearmind Medicine Price Performance

The business has a 50 day moving average of $1.76 and a 200 day moving average of $5.01. The firm has a market capitalization of $999,600.00, a price-to-earnings ratio of -0.01 and a beta of 0.81.

Clearmind Medicine (NASDAQ:CMND) last announced its quarterly earnings results on Thursday, September 10th. The company reported ($0.57) earnings per share (EPS) for the quarter.

Insider Buying and Selling

In other news, major shareholder Financial Lp Hrt sold 22,139 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $3.31, for a total value of $73,280.09. Following the sale, the insider directly owned 81,353 shares in the company, valued at approximately $269,278.43. This represents a 21.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold a total of 27,424 shares of company stock worth $90,910 in the last three months.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.